GeoVax Labs Inc. (NASDAQ:GOVX) Stock Short Interest Report for September

GeoVax Labs Inc. (NASDAQ:GOVX) was the target of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totaling 281,773 shares, a decrease of 43.5% from the September 15th total of 498,698 shares. Currently, 3.8% of the shares of the company are short sold. Based on an average daily trading volume, of 241,876 shares, the short-interest ratio is currently 1.2 days.

GeoVax Labs Stock Performance

GeoVax Labs stock traded down $0.02 during trading hours on Friday, hitting $0.24. 145,595 shares of the stock were exchanged, compared to its average volume of 934,233. The stock has a market capitalization of $1.76 million, a P/E ratio of -0.02 and a beta of 3.69. The business’s 50-day moving average is $0.47 and its two-hundred day moving average is $1.06. GeoVax Labs has a 12 month low of $0.23 and a 12 month high of $15.25.

GeoVax Labs (NASDAQ:GOVX) last announced its earnings results on Monday, July 27th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($2.16) by $1.19. On average, equities analysts predict that GeoVax Labs will post -4.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on GOVX. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Thursday. Noble Financial restated an “outperform” rating on shares of GeoVax Labs in a research note on Tuesday, September 15th. Finally, Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a report on Sunday, June 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, GeoVax Labs presently has a consensus rating of “Hold” and a consensus price target of $150.00.

About GeoVax Labs

GeoVax Labs, Inc is a biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and cancer. The company’s research is based primarily on a vaccine platform that combines a modified vaccinia Ankara (MVA) viral vector with virus-like particles (VLPs) to stimulate both antibody and cellular immune responses.

GeoVax’s development programs have included GEO-CM04S1, a next-generation COVID-19 vaccine candidate; GOVX-B11, an investigational HIV vaccine designed to generate broadly protective immune responses; and GOVX-CHIKV, a vaccine candidate targeting chikungunya virus.